A. Orleth

发表

A Hybrid Model of Nucleotide Excision Repair in Neoplastic diseases and in vitro Experiments

P. Valigi, L. Crinò, M. Tonato, 2006 .

Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth

Andreas Wicki, Gerhard Christofori, Richard Herrmann, 2011, Clinical Cancer Research.

Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair.

Natalia Meani, Myriam Alcalay, Daniela Riganelli, 2003, The Journal of clinical investigation.

Generating evidence on a risk-based monitoring approach in the academic setting – lessons learned

M. Briel, P. Benkert, C. Pauli–Magnus, 2017, BMC Medical Research Methodology.

Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML).

S. Pileri, L. Pasqualucci, B. Falini, 1997, Blood.

Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors

G. Christofori, C. Mamot, C. Rochlitz, 2014, EJNMMI Research.

Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS

C. Granziera, L. Kappos, T. Derfuss, 2022, Annals of neurology.

Common themes in the pathogenesis of acute myeloid leukemia

S. Minucci, P. Pelicci, F. Chiaradonna, 2001, Oncogene.

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study

D. Conen, K. Blennow, C. Granziera, 2022, The Lancet Neurology.

Erratum: PML is required for telomere stability in non-neoplastic human cells

S. Minucci, P. Pelicci, M. Faretta, 2016, Oncogene.

PAX5 Expression in Acute Leukemias

S. Pileri, B. Falini, F. Lo‐Coco, 2004, Cancer Research.

PAX 5 Expression in Acute Leukemias : Higher B-Lineage Specificity Than CD 79 a and Selective Association with t ( 8 ; 21 )-Acute Myelogenous Leukemia

S. Pileri, B. Falini, F. Lo‐Coco, 2004 .

Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy

K. Alitalo, G. Christofori, C. Mamot, 2016, Journal of drug targeting.

Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells

Myriam Alcalay, Pier Giuseppe Pelicci, Andrea Viale, 2009, Nature.

Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis

D. Conen, C. Granziera, L. Kappos, 2021, Annals of neurology.

Abstracts of the 113th Annual Meeting of the Swiss Neurological Society, Congress Centre Kursaal Interlaken, Switzerland, November 18–19, 2021

R. Pedotti, T. Derfuss, M. Mehling, 2021 .

Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis

F. Piehl, J. Kira, J. Lambert, 2023, Journal of Neurology, Neurosurgery, and Psychiatry.

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.

M. Battaglini, C. Granziera, L. Kappos, 2023, JAMA neurology.

The acute promyelocytic leukaemia specific PML and PLZF proteins localize to adjacent and functionally distinct nuclear bodies

P. Pelicci, M. Fagioli, R. Mannucci, 1998, Oncogene.

With the Monoclonal Antibody PGM 3 ( Anti-PML ) Immunocytochemical Diagnosis of Acute Promyelocytic Leukemia ( M 3 )

S. Pileri, L. Pasqualucci, P. Pelicci, 1997 .

PML is required for telomere stability in non-neoplastic human cells

S. Minucci, P. Pelicci, M. Faretta, 2015, Oncogene.